FDA Pulmonary Division Director Jenkins To Head ODE II; Bilstad To Head QA
Executive Summary
FDA Pulmonary Drug Products Division Director John Jenkins, MD, has been selected to head FDA's Office of Drug Evaluation II, beginning April 25.
You may also be interested in...
FDA And EMEA To Compare Regulatory Approaches Used In 1998 NME Cohort
FDA and the European Medicines Evaluation Agency will conduct a joint assessment of the approaches used by the two agencies in the 1998 cohort of new molecular entity reviews.
FDA And EMEA To Compare Regulatory Approaches Used In 1998 NME Cohort
FDA and the European Medicines Evaluation Agency will conduct a joint assessment of the approaches used by the two agencies in the 1998 cohort of new molecular entity reviews.
FDA ODE II Overhaul Continues: Rarick Returns, Sobel Moves Up
FDA is completing a change of the guard in the Office of Drug Evaluation II with the appointment of Reproductive & Urologic Drug Products Division Director Lisa Rarick, MD, as ODE II deputy director.